Summary by Moomoo AI
Conch Pharmaceuticals (CMS) announced that its new drug Alocotine Phosphate Ointment has been approved for listing in Macau and received the drug registration certificate on April 16, 2024. This product is used to treat non-segmented leucorrhoea in patients aged 12 years and older. In addition, Locotinic Cream has been approved in the United States and Europe, and has officially landed in the Boao Le Cheng International Medical Tourism Pioneering Zone in Hainan. Conge Beauty entered into a cooperation and licensing agreement with Incyte for the product, obtaining exclusive licensing rights in designated Asian regions. The company is promoting the commercialization of Locotini cream in Macau to benefit local rubella patients.